Skip Nav Destination
1-20 of 41
Nikhil S. Patil, Amin Hatamnejad, Andrew Mihalache, Marko M. Popovic, Peter J. Kertes, Rajeev H. Muni
Ophthalmologica (2022) 245 (6): 500–515.
Published Online: 16 November 2022
... to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. 2022 Aflibercept Bevacizumab Dexamethasone Ranibizumab Triamcinolone acetonide Retinal vein occlusions (RVOs) are one of the leading causes of vision loss...
Ophthalmologica (2022) 245 (2): 161–172.
Published Online: 29 November 2021
...Sadik Etka Bayramoglu; Nihat Sayin Introduction: In this study, we investigated the effect of drug dose on the progression of retinal vascularization in eyes treated with different doses of intravitreal bevacizumab (IVB). Methods: The patient charts of 259 eyes of 142 patients who were administered...
Ophthalmologica (2022) 245 (1): 19–24.
Published Online: 10 September 2021
...Ori Segal; Roy Yavnieli; Michael Mimouni; Gilad Rabina; Noa Geffen; Elad Moisseiev; Arie Y. Nemet Purpose: This study aimed to identify baseline optical coherence tomography (OCT) factors in branch retinal vein occlusion (BRVO) that predict response to bevacizumab injections. Methods...
Ophthalmologica (2022) 245 (1): 34–40.
Published Online: 23 July 2021
... factor Bevacizumab Endophthalmitis Filling Prefilled syringe Ranibizumab Syringe Intravitreal injections of anti-vascular endothelial growth factor (VEGF) agents are the most commonly performed procedure in ophthalmology [1-3]. These agents have been established as a safe and effective...
Gregg T. Kokame, Mark W. Johnson, Jennifer Lim, Harry W. Flynn, Talisa de Carlo, Nicolas Yannuzzi, Edwin H. Ryan, Jase N. Omizo, Jayanth Sridhar, Patrick Staropoli, Brian Goldhagen, Rebecca Lian
Ophthalmologica (2022) 245 (2): 179–186.
Published Online: 28 June 2021
... Bevacizumab Ketorolac Prednisolone Carbonic anhydrase inhibitors Macular holes are full-thickness anatomic defects in the fovea from the internal limiting membrane (ILM) to the retinal pigment epithelium and are most commonly related to vitreous traction on the macula . Because of the need...
Ophthalmologica (2018) 240 (3): 163–166.
Published Online: 31 August 2018
...Omer Trivizki; Shulamit Schwartz; Neta Negri; Anat Loewenstein; Gilad Rabina; Shiri Shulman Purpose: To report a cluster of high incidence of noninfectious inflammatory reaction shortly after bevacizumab injection. Methods: Data were collected from medical records of consecutive patients who...
Ophthalmologica (2019) 241 (3): 137–142.
Published Online: 12 July 2018
.... In this study, we investigate the effects of ranibizumab (Lucentis®), bevacizumab (Avastin®), and aflibercept (Eylea®) on primary human retinal pigment epithelial (hRPE) cells in vitro. Methods: hRPE cells were prepared from donor eyes and cultured under standard culture conditions. Scleral fibroblasts also...
Ophthalmologica (2018) 240 (2): 99–105.
Published Online: 19 June 2018
...Sabit Kimyon; Alper Mete Purpose: To investigate the effects of bevacizumab and ranibizumab in the treatment of type 1 retinopathy of prematurity (ROP) affecting zone 1. Methods: Files of the patients who received intravitreal bevacizumab (IVB) or ranibizumab (IVR) treatment for ROP affecting zone...
Ophthalmologica (2018) 239 (4): 194–204.
Published Online: 31 January 2018
...Donghyoun Noh; Gahyung Ryu; Junyeop Lee; Min Sagong Purpose: To evaluate whether early anatomical and visual acuity (VA) responses to intravitreal bevacizumab (IVB) in macular edema secondary to branch retinal vein occlusion (BRVO) are associated with 1-year follow-up outcomes. Methods: Ninety-nine...
Ophthalmologica (2017) 238 (4): 217–225.
Published Online: 20 September 2017
... re nata and quarterly treatment regimens have yielded less effective results over 1-2 years in most studies [ 4,5,6,7,8,9,10 ]. Intravitreal bevacizumab (Avastin; Genentech Inc.) is another inhibitor of VEGF-A receptor that is widely used for the treatment of neovascular AMD. It is a full-length...
Frank Enseleit, Stephan Michels, Isabella Sudano, Marc Stahel, Sandrine Zweifel, Oliver Schlager, Matthias Becker, Stephan Winnik, Matthias Nägele, Andreas J. Flammer, Michel Neidhart, Nicole Graf, Christian M. Matter, Burkhardt Seifert, Thomas F. Lüscher, Frank Ruschitzka
Ophthalmologica (2017) 238 (4): 205–216.
Published Online: 02 September 2017
... with neovascular and dry AMD were enrolled. Eligible neovascular AMD patients received 2 intravitreal loading doses of either ranibizumab 0.5 mg or bevacizumab 1.25 mg at 4-week intervals and were subsequently followed every 4 weeks and treated according to a pro re nata regime for up to 1 year. Patients with dry...
Ophthalmologica (2017) 238 (3): 147–153.
Published Online: 10 June 2017
...Muhammed Mustafa Kurt; Osman Çekiç; Çetin Akpolat; Murat Aslankurt; Mustafa Nuri Elçioğlu Purpose: The aim of this paper was to assess and compare the effects of intravitreal ranibizumab and bevacizumab on retinal vessel diameter in eyes with neovascular age-related macular degeneration (AMD...
Ophthalmologica (2017) 238 (1-2): 110–118.
Published Online: 24 May 2017
...Joel Hanhart; Yaacov Rozenman Purpose: To compare the visual and anatomic outcomes of macular edema secondary to retinal vein occlusion after switching from bevacizumab to ranibizumab, aflibercept, or dexamethasone implant. Methods: Fifteen eyes were switched to ranibizumab, 12 to aflibercept...
Ophthalmologica (2016) 236 (3): 139–147.
Published Online: 29 September 2016
...Emine Alyamaç Sukgen; Aysegül Çömez; Yusuf Koçluk; Selim Cevher Purpose: To compare the effects on the process of retinal vascularization of intravitreal ranibizumab (IVR) and intravitreal bevacizumab (IVB) in the treatment of severe retinopathy of prematurity. Methods: The present study is a bi...
Subject Area:Topic Article Package: Diabetes 2016 , Topic Article Package: Diabetes , Ophthalmology
Ophthalmologica (2016) 235 (3): 133–136.
Published Online: 01 March 2016
...Rita Ehrlich; Idit Dan; Iris Deitch; Ruth Axer-Siegel; Karin Mimouni Purpose: To investigate the response to intravitreal ranibizumab after failure of intravitreal bevacizumab in patients with diabetic macular edema (DME). Methods: Demographics, visual acuity (VA), central macular thickness (CMT...
Bianka Sobolewska, Cornelia Grimmel, Aikaterini Gatsiou, Kateryna Sopova, Judith Klein, Tilo Biedermann, Konstantinos Stellos, Focke Ziemssen
Ophthalmologica (2015) 234 (4): 195–210.
Published Online: 21 August 2015
...Bianka Sobolewska; Cornelia Grimmel; Aikaterini Gatsiou; Kateryna Sopova; Judith Klein; Tilo Biedermann; Konstantinos Stellos; Focke Ziemssen Purpose: The aim of the study was to evaluate the potential influence of ranibizumab and bevacizumab on platelet activation and aggregation, which...
Ophthalmologica (2015) 234 (2): 109–118.
Published Online: 19 August 2015
... after intravitreal bevacizumab (IVB) injections. Results: Regional choroidal thickness was measured in 57 eyes at baseline. The mean choroidal thickness of the occlusive area was significantly higher than that of the nonocclusive, subfoveal, and corresponding areas in the fellow eyes and normal controls...
João Pinheiro-Costa, José M. Costa, João N. Beato, Paulo Freitas-da-Costa, Elisete Brandão, Manuel S. Falcão, Fernando Falcão-Reis, Ângela M. Carneiro
Ophthalmologica (2015) 233 (3-4): 155–161.
Published Online: 17 April 2015
... degeneration (AMD) switched from intravitreal bevacizumab or ranibizumab. Methods: This is a retrospective review of eyes with neovascular AMD switched to intravitreal aflibercept with at least 1 year of follow-up after the switch. All patients had had a minimum of 3 injections of bevacizumab or ranibizumab...
João Pinheiro-Costa, Paulo Freitas-da-Costa, Manuel S. Falcão, Elisete M. Brandão, Fernando Falcão-Reis, Ângela M. Carneiro
Ophthalmologica (2014) 232 (3): 149–155.
Published Online: 29 August 2014
...João Pinheiro-Costa; Paulo Freitas-da-Costa; Manuel S. Falcão; Elisete M. Brandão; Fernando Falcão-Reis; Ângela M. Carneiro Objective: To compare outcomes after switching from intravitreal ranibizumab to bevacizumab in neovascular age-related macular degeneration (AMD). Methods: A retrospective...
Ophthalmologica (2014) 232 (1): 53–56.
Published Online: 20 May 2014
... Ranibizumab Lucentis Bevacizumab Avastin Tachyphylaxis Resistance References 1. Congdon N, O'Colmain B, Klaver CC, et al: Causes and prevalence of visual impairment among adults in United States: Eye Diseases Prevalence Research Group. Arch Ophthalmol 2004;122:477-485. 2. Comparison...